Diagnostic Approach to Paroxysmal Nocturnal Hemoglobinuria (PNH)
Clinical Presentations and Diagnostic Evaluation
- Unexplained intravascular hemolysis with evidence of hemolysis on peripheral smear is an indication for PNH testing, according to the Journal of Clinical Oncology 1
- Venous thrombosis in unusual sites, particularly splanchnic vein thrombosis, is a clinical presentation that warrants PNH testing, as reported by the Journal of Hepatology 2, 3
- Cytopenias associated with bone marrow failure syndromes, such as those described by the National Comprehensive Cancer Network, are an indication for PNH testing 4, 5
- Unexplained hemolytic anemia with negative direct antiglobulin test is a condition that may require PNH testing, as suggested by the Journal of Clinical Oncology 1
- Young patients with normal cytogenetics and hypoplastic myelodysplastic syndrome are at risk for PNH, according to the National Comprehensive Cancer Network 4, 6
- Budd-Chiari syndrome is associated with an underlying PNH diagnosis in 9-19% of patients, as reported by the Journal of Hepatology 3
Diagnostic Algorithm and Testing
- Complete blood count with differential and reticulocyte count is a recommended initial laboratory evaluation, as suggested by the Journal of Clinical Oncology 7
- Peripheral blood smear examination for evidence of hemolysis is a crucial diagnostic step, according to the Journal of Clinical Oncology 1
- Hemolysis markers, including LDH, haptoglobin, bilirubin, and free hemoglobin, should be evaluated, as recommended by the Journal of Clinical Oncology 1
- Renal function tests and coagulation profile are essential components of the initial laboratory evaluation, as suggested by the Journal of Clinical Oncology 7, 1
- JAK2V617F mutation testing and thrombophilia screening may be necessary for patients with thrombosis, as reported by the Journal of Hepatology 8
- Bone marrow aspiration and biopsy, as well as cytogenetic analysis, are recommended for patients with cytopenias, according to the National Comprehensive Cancer Network 6, 4, 5
Interpretation of Results and Clinical Correlation
- Patients with >60% PNH granulocytes have a higher thrombosis risk, as reported by the Journal of Hepatology 3
- PNH can occur in association with other bone marrow failure syndromes, such as aplastic anemia and MDS, as described by the National Comprehensive Cancer Network 4, 5
- Patients with splanchnic vein thrombosis should be routinely tested for PNH, especially those with Budd-Chiari syndrome, as recommended by the Journal of Hepatology 8
Paroxysmal Nocturnal Hemoglobinuria: Evidence‑Based Diagnostic and Therapeutic Recommendations
Diagnostic Approach
Flow cytometry detecting deficiency of the GPI‑anchored proteins CD55 and CD59 on peripheral blood cells is the definitive diagnostic test for PNH and should be performed in every patient with suspected disease. The test evaluates granulocytes, monocytes, and red blood cells and is considered the gold‑standard assay. 9, 10
Unexplained venous thrombosis at atypical sites (splanchnic veins, hepatic, portal, mesenteric veins) or Budd‑Chiari syndrome warrants PNH testing; 9–19 % of patients with Budd‑Chiari have an underlying PNH clone. 11
Cytopenias occurring in the context of bone‑marrow failure syndromes—such as aplastic anemia or hypoplastic myelodysplastic syndrome with normal cytogenetics—should trigger PNH evaluation. 9, 10
Additional Laboratory and Genetic Testing
In patients presenting with thrombosis, JAK2 V617F mutation analysis and a comprehensive thrombophilia screen are recommended to exclude concurrent myeloproliferative neoplasms. 11
For individuals with cytopenias, bone‑marrow aspiration and biopsy with cytogenetic analysis are advised to differentiate PNH‑associated aplastic anemia or myelodysplastic syndrome from other marrow disorders. 9, 10
Supportive Care and Curative Options
Transfusion support: Packed red‑blood‑cell transfusions should be given for symptomatic anemia; all blood products must be irradiated and leukocyte‑filtered when a concurrent bone‑marrow failure syndrome is present. 9, 10
Allogeneic hematopoietic stem‑cell transplantation (HSCT) is the only curative therapy and should be considered for patients with severe bone‑marrow failure (e.g., severe aplastic anemia with a PNH clone) and for young, well‑matched donors when disease is life‑threatening or refractory to complement inhibition. HSCT is not first‑line because of its inherent morbidity and mortality. 9, 10
PNH Clone Size and Clinical Management
Prognostic Significance of Clone Size
- A PNH clone > 60 % of granulocytes identifies patients at markedly increased risk of thrombosis and severe hemolysis, representing a high‑risk phenotype that typically presents with classic hemolytic PNH. 12
- A PNH clone of 1–10 % is frequently linked to bone‑marrow failure syndromes such as aplastic anemia and myelodysplastic syndrome; these small clones may be clinically silent but can expand over time. 13
Indications for PNH Clone Testing
- Unexplained intravascular hemolysis, venous thrombosis at atypical sites (especially splanchnic veins), and cytopenias associated with hypoplastic marrow or normal cytogenetics should prompt PNH flow‑cytometry; 9–19 % of patients with Budd‑Chiari syndrome are found to have underlying PNH. 12
- The presence of cytopenias in the context of bone‑marrow failure syndromes—particularly hypoplastic myelodysplastic syndrome or aplastic anemia—warrants PNH clone assessment. 13
Risk Stratification and Therapeutic Recommendations
- Clones ≥ 60 % with active hemolysis or prior thrombosis – immediate evaluation for complement‑inhibitor therapy (e.g., eculizumab) and comprehensive thrombophilia screening, including JAK2V617F testing, to exclude co‑existent myeloproliferative neoplasms. 12
- Clones 10–60 % – close clinical monitoring with serial CBC and LDH; anticoagulation should be considered if any thrombotic event occurs, regardless of clone size. 12
- Clones 1–10 % associated with bone‑marrow failure – primary management focuses on treating the underlying aplastic anemia or MDS; serial flow‑cytometry every 6–12 months is recommended to detect clone expansion. 13
- Lifelong anticoagulation is advised for any patient who has experienced a thrombotic event, given the high recurrence risk in PNH. 12
Monitoring and Follow‑up
- Routine reassessment of PNH clone size every 6–12 months by flow cytometry; an increase in clone percentage signals heightened risk for hemolysis and thrombosis. 13
- Ongoing surveillance for atypical site thrombosis (e.g., Budd‑Chiari syndrome) remains essential in all patients with a detectable clone. 12
Clinical Pitfalls to Avoid
- Small clones (1–10 %) should not be dismissed as irrelevant; they may enlarge and are often linked to bone‑marrow failure, necessitating appropriate management. 13
- Anticoagulation must not be delayed in patients with thrombosis, even when the PNH clone is modest, because PNH‑related thrombosis carries high mortality. 12
- Concurrent hematologic disorders (aplastic anemia, MDS) are common in PNH and require bone‑marrow evaluation to guide therapy. 13